Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP)

Barclays PLC boosted its holdings in Rapport Therapeutics (NASDAQ:RAPP) by 36.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,863 shares of the company’s stock after purchasing an additional 3,463 shares during the quarter. Barclays PLC’s holdings in Rapport Therapeutics were worth $264,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. purchased a new stake in Rapport Therapeutics in the 3rd quarter valued at about $1,498,000. Millennium Management LLC acquired a new stake in shares of Rapport Therapeutics in the second quarter worth approximately $2,716,000. Perceptive Advisors LLC purchased a new stake in Rapport Therapeutics in the second quarter valued at approximately $17,403,000. ARCH Venture Management LLC acquired a new position in Rapport Therapeutics during the second quarter worth approximately $86,730,000. Finally, Geode Capital Management LLC purchased a new position in Rapport Therapeutics during the third quarter worth approximately $4,133,000.

Rapport Therapeutics Trading Up 1.4 %

Shares of RAPP opened at $12.69 on Tuesday. Rapport Therapeutics has a fifty-two week low of $12.09 and a fifty-two week high of $29.74. The company’s fifty day moving average is $19.43 and its two-hundred day moving average is $21.20.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.